On Monday, Shares of Chesapeake Energy Corporation (NYSE:CHK), lost -6.12% to $10.27, as Oil futures fell on Monday and U.S. crude slipped below $50 a barrel intraday as ample supply, the prospect of more Iranian crude for export and a strengthening dollar combined to pressure prices.
Brent September crude LCOc1 fell 45 cents to settle at $56.65 a barrel, having traded between $56.33 and $57.44.
U.S. August crude CLc1, set to expire on Tuesday, fell 74 cents to settle at $50.15, having fallen to $49.85, its first time below $50 since April, according to Reuters.
Chesapeake Energy Corporation produces oil and natural gas through acquisition, exploration, and development of from underground reservoirs in the United States.
Shares of American Realty Capital Properties, Inc. (NASDAQ:ARCP), declined -0.69% to $8.62, during its last trading session.
American Realty Capital Properties, declared recently that it will transfer the listing of its common stock (“Common Stock”), par value $0.01 per share, and 6.70% Series F Cumulative Redeemable Preferred Stock (“Series F Preferred Stock”), par value $0.01 per share, from the NASDAQ Global Select Market (“NASDAQ”) to the New York Stock Exchange (“NYSE”). The Company anticipates to start trading on the NYSE on July 31, 2015. Until the opening of trading July 31, 2015, when the Company anticipates the Common Stock and Series F Preferred Stock will start to trade on the NYSE under a new, soon-to-be declared corporate name and ticker symbols, each of the Common Stock and Series F Preferred Stock will continue to trade on the NASDAQ under the ticker symbols ARCP and ARCPP, respectively.
American Realty Capital Properties, Inc. owns and acquires single tenant, freestanding commercial real estate that is net leased on a medium-term basis, primarily to investment grade credit rated and other creditworthy tenants.
Finally, Allergan plc (NYSE:AGN), ended its last trade with 0.49% gain, and closed at $317.75.
Allergan, confirmed that the Company has received a notice letter dated July 10, 2015 (the “Notice Letter”) from Akorn Pharmaceuticals stating that the U.S. Food and Drug Administration (FDA) has received Akorn’s Abbreviated New Drug Application (ANDA) containing a “Paragraph IV” patent certification seeking approval to market a generic version of Allergan’s Restasis® (cyclosporine ophthalmic emulsion) 0.05% product. In addition, Allergan has received communication suggesting that additional ANDAs for generic versions of Restasis® may have been received by the FDA.
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
